Rates of latent tuberculosis infection in patients treated with TNF inhibitors for psoriasis: a retrospective chart review
Background: Although tuberculosis screening guidelines for psoriasis patients on TNF inhibitors exist, few studies have reported the prevalence of latent tuberculosis infection (LTBI) and conversion rates in this population. Objective: To determine the incidence of LTBI and active tuberculosis in pa...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2018-10-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/09546634.2018.1443198 |
| _version_ | 1797683721533390848 |
|---|---|
| author | Erica B. Lee Mina Amin Jeremy Man Alexander Egeberg Jashin J. Wu |
| author_facet | Erica B. Lee Mina Amin Jeremy Man Alexander Egeberg Jashin J. Wu |
| author_sort | Erica B. Lee |
| collection | DOAJ |
| description | Background: Although tuberculosis screening guidelines for psoriasis patients on TNF inhibitors exist, few studies have reported the prevalence of latent tuberculosis infection (LTBI) and conversion rates in this population. Objective: To determine the incidence of LTBI and active tuberculosis in patients with psoriasis receiving TNF inhibitor therapy. Methods: A total of 138 patients were included in our retrospective study of patients treated from September 2004 to September 2017. Tuberculin skin test was considered positive with an induration of greater than 5 mm. History of Bacillus Calmette-Guérin vaccination, follow-up tests and prophylaxis were recorded. Results: Among 99 biologic-naïve patients, 14 had LTBI before starting biologic therapy and five developed LTBI during TNF inhibitor therapy. One biologic-naïve patient developed LTBI, then active tuberculosis. Among 39 non-biologic-naïve patients, three had LTBI before starting any biologic therapy, and one developed LTBI during treatment. Limitations: Limitations include small sample size and limited information documented in the medical chart. Conclusions: LTBI appears to be prevalent among psoriasis patients. Screening for LTBI in patients on biologics may reduce risk of active tuberculosis; however, current methods may not be fully effective. Clinicians may need to use other tools including risk factor assessment to fully evaluate risk. |
| first_indexed | 2024-03-12T00:18:52Z |
| format | Article |
| id | doaj.art-0ff7a29f8d984f259d5e224f4a591927 |
| institution | Directory Open Access Journal |
| issn | 0954-6634 1471-1753 |
| language | English |
| last_indexed | 2024-03-12T00:18:52Z |
| publishDate | 2018-10-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj.art-0ff7a29f8d984f259d5e224f4a5919272023-09-15T14:08:32ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532018-10-0129767167510.1080/09546634.2018.14431981443198Rates of latent tuberculosis infection in patients treated with TNF inhibitors for psoriasis: a retrospective chart reviewErica B. Lee0Mina Amin1Jeremy Man2Alexander Egeberg3Jashin J. Wu4John A. Burns School of Medicine, University of HawaiiSchool of Medicine, University of CaliforniaKaiser Permanente Los Angeles Medical CenterHerlov and Gentofte HospitalKaiser Permanente Los Angeles Medical CenterBackground: Although tuberculosis screening guidelines for psoriasis patients on TNF inhibitors exist, few studies have reported the prevalence of latent tuberculosis infection (LTBI) and conversion rates in this population. Objective: To determine the incidence of LTBI and active tuberculosis in patients with psoriasis receiving TNF inhibitor therapy. Methods: A total of 138 patients were included in our retrospective study of patients treated from September 2004 to September 2017. Tuberculin skin test was considered positive with an induration of greater than 5 mm. History of Bacillus Calmette-Guérin vaccination, follow-up tests and prophylaxis were recorded. Results: Among 99 biologic-naïve patients, 14 had LTBI before starting biologic therapy and five developed LTBI during TNF inhibitor therapy. One biologic-naïve patient developed LTBI, then active tuberculosis. Among 39 non-biologic-naïve patients, three had LTBI before starting any biologic therapy, and one developed LTBI during treatment. Limitations: Limitations include small sample size and limited information documented in the medical chart. Conclusions: LTBI appears to be prevalent among psoriasis patients. Screening for LTBI in patients on biologics may reduce risk of active tuberculosis; however, current methods may not be fully effective. Clinicians may need to use other tools including risk factor assessment to fully evaluate risk.http://dx.doi.org/10.1080/09546634.2018.1443198psoriasistumor necrosis factor inhibitorsbiologicstuberculosisadalimumabetanercept |
| spellingShingle | Erica B. Lee Mina Amin Jeremy Man Alexander Egeberg Jashin J. Wu Rates of latent tuberculosis infection in patients treated with TNF inhibitors for psoriasis: a retrospective chart review Journal of Dermatological Treatment psoriasis tumor necrosis factor inhibitors biologics tuberculosis adalimumab etanercept |
| title | Rates of latent tuberculosis infection in patients treated with TNF inhibitors for psoriasis: a retrospective chart review |
| title_full | Rates of latent tuberculosis infection in patients treated with TNF inhibitors for psoriasis: a retrospective chart review |
| title_fullStr | Rates of latent tuberculosis infection in patients treated with TNF inhibitors for psoriasis: a retrospective chart review |
| title_full_unstemmed | Rates of latent tuberculosis infection in patients treated with TNF inhibitors for psoriasis: a retrospective chart review |
| title_short | Rates of latent tuberculosis infection in patients treated with TNF inhibitors for psoriasis: a retrospective chart review |
| title_sort | rates of latent tuberculosis infection in patients treated with tnf inhibitors for psoriasis a retrospective chart review |
| topic | psoriasis tumor necrosis factor inhibitors biologics tuberculosis adalimumab etanercept |
| url | http://dx.doi.org/10.1080/09546634.2018.1443198 |
| work_keys_str_mv | AT ericablee ratesoflatenttuberculosisinfectioninpatientstreatedwithtnfinhibitorsforpsoriasisaretrospectivechartreview AT minaamin ratesoflatenttuberculosisinfectioninpatientstreatedwithtnfinhibitorsforpsoriasisaretrospectivechartreview AT jeremyman ratesoflatenttuberculosisinfectioninpatientstreatedwithtnfinhibitorsforpsoriasisaretrospectivechartreview AT alexanderegeberg ratesoflatenttuberculosisinfectioninpatientstreatedwithtnfinhibitorsforpsoriasisaretrospectivechartreview AT jashinjwu ratesoflatenttuberculosisinfectioninpatientstreatedwithtnfinhibitorsforpsoriasisaretrospectivechartreview |